COVID-2019 hyperimmune globulin - Intas Pharma
Alternative Names: COVID-19 hyperimmune globulinLatest Information Update: 28 May 2024
At a glance
- Originator Intas Pharmaceuticals
- Class Antivirals; Polyclonal antibodies
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in India (IV, Injection)
- 28 Aug 2020 Intas Pharmaceuticals plans a phase II trial for COVID-2019 infections (Adjuvant therapy) in India (CTRI/2020/09/027903)
- 27 Apr 2020 Preclinical trials in COVID-2019 infections in India (IV), before April 2020